Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection

医学 外科 胶质母细胞瘤 切除术 回顾性队列研究 化疗 多中心研究 并发症 外科切除术 随机对照试验 癌症研究
作者
Florian A. Ringel,Haiko Pape,Michael Sabel,Dietmar Krex,Hans Christoph Bock,Martin Misch,Astrid Weyerbrock,Thomas Westermaier,Christian Senft,Philippe Schucht,Bernhard Meyer,Matthias Simon
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:18 (1): 96-104 被引量:267
标识
DOI:10.1093/neuonc/nov145
摘要

BACKGROUND: While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recurrent glioblastomas on patient survival. METHODS: In a multicenter retrospective-design study, patients with primary glioblastomas undergoing repeat resections for recurrent tumors were evaluated for factors affecting survival. Age, Karnofsky performance status (KPS), extent of resection (EOR), tumor location, and complications were assessed. RESULTS: Five hundred and three patients (initially diagnosed between 2006 and 2010) undergoing resections for recurrent glioblastoma at 20 institutions were included in the study. The patients' median overall survival after initial diagnosis was 25.0 months and 11.9 months after first re-resection. The following parameters were found to influence survival significantly after first re-resection: preoperative and postoperative KPS, EOR of first re-resection, and chemotherapy after first re-resection. The rate of permanent new deficits after first re-resection was 8%. CONCLUSION: The present study supports the view that surgical resections of recurrent glioblastomas may help to prolong patient survival at an acceptable complication rate.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐的应助被dahe采纳,获得30
刚刚
兴奋冬萱完成签到,获得积分20
刚刚
在水一方的应助被猪猪hero采纳,获得10
刚刚
1秒前
兴奋冬萱发布了新的文献求助10
2秒前
2秒前
彭于晏的应助被一条好ham采纳,获得10
2秒前
3秒前
搜集达人的应助被kakka1316采纳,获得10
3秒前
4秒前
lkx发布了新的文献求助10
4秒前
4秒前
4秒前
风中小丸子完成签到 ,获得积分10
4秒前
Jasper的应助被JayChou采纳,获得10
4秒前
烟花的应助被理工彭于晏采纳,获得10
5秒前
救我完成签到,获得积分10
5秒前
坚强的夏真完成签到 ,获得积分10
5秒前
6秒前
yzp111完成签到,获得积分10
6秒前
6秒前
111发布了新的文献求助10
7秒前
huicheng的应助被zpctx采纳,获得10
8秒前
NexusExplorer的应助被333455采纳,获得10
8秒前
8秒前
8秒前
Ava的应助被songsong采纳,获得10
8秒前
wwq发布了新的文献求助20
9秒前
9秒前
9秒前
DW的应助被wxy采纳,获得10
9秒前
科研通AI6.2的应助被wxy采纳,获得10
9秒前
9秒前
soso的应助被wxy采纳,获得50
9秒前
rjx发布了新的文献求助10
10秒前
10秒前
学术雷锋的应助被wxy采纳,获得10
10秒前
10秒前
初(*^▽^*)心的应助被wxy采纳,获得10
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Mathematical models in hydrology 1000
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Erzählte Gnade 500
Butadiene hydroxytelechelic oligomers PBHT 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8082237
求助须知:如何正确求助?哪些是违规求助? 9497698
关于积分的说明 21402759
捐赠科研通 7650383
什么是DOI,文献DOI怎么找? 3401777
关于科研通互助平台的介绍 2530949
邀请新用户注册赠送积分活动 2440452